New consortium formed to develop cell-based cancer vaccines

By The Science Advisory Board staff writers

June 17, 2020 -- A new consortium has been formed to increase access to cell-based cancer vaccines by using single-use technology to develop and manufacture dendritic cell cancer vaccines.

The collaboration among Saint-Gobain Life Sciences, Kanyr Pharma (a McGill University startup), the Research Institute at the McGill University Health Center, and McGill University's Stem Cell Bioprocessing Laboratory and Plasma Processing Laboratory will develop the vaccine in Saint-Gobain's VueLife "C" Series fluorinated ethylene propylene bags. This single-use option will allow for closed system culture and manufacturing and enable researchers to easily move research-scale bioprocesses to clinical-scale commercial production.

Interdisciplinary partnership between Saint-Gobain, Kanyr Pharma, and McGill in the development of optimized culture environments for dendritic cell cancer vaccines.
Interdisciplinary partnership between Saint-Gobain, Kanyr Pharma, and McGill in the development of optimized culture environments for dendritic cell cancer vaccines. Image courtesy of Saint-Gobain.

Additionally, Kanyr's Immunyr technology will be incorporated to obtain pharmacologically activated dendritic cells using a proprietary small inhibitor of key phosphatase enzymes. Immunyr was developed to activate each patient's own immune system to target several types of cancer.

Researchers will study protein-surface and cell-surface interactions in realistic bioprocessing conditions to accelerate clinical development. Immunyr will be used to develop several cancer vaccine therapeutic applications and to further demonstrate the value of VueLife bags for cell therapy applications.


Copyright © 2020 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.